-
Part 1 of 2: Indications, Mechanism of Action, Pharmacokinetics, Dosing & Administration, Adverse Events, amd Interactions. Cinacalcet is the first in a class of calcimimetic agents that increases the sensitivity of the calcium-sensing receptor to activation by extracellular calcium.
-
Hydromorphone hydrochloride (Palladone); New indication for duloxetine hydrochloride (Cymbalta).
-
Rofecoxib, celecoxib (Celebrex), and valdecoxib (Bextra) are a subclass of nonsteroidal anti-inflammatory drugs (NSAIDs) that selectively block the enzyme COX-2 (cyclooxygenase-2). When Merck announced the rofecoxib withdrawal, it said that its study results were not necessarily applicable to others in the COX-2 inhibitor class.
-
Merck announced on September 30th that it is voluntarily withdrawing rofecoxib (Vioxx) from the worldwide market.
-
Physicians increasingly are aware of the need to provide prophylaxis against venous thrombosis for the medically ill patient in the hospital environment. This article attempts to separate the fact from fiction regarding VTE prophylaxis.
-
New salary statistics show that hospital pharmacy administrators may make $100,000 or more and work 50 hours a week or fewer. Even so, pharmacy management positions are some of the hardest to fill, according to a second survey.
-
Oral erythromycin, CYP3A inhibitor combination risky; Many patients dont tell docs about medication underuse; Scientists find potential way to control drug-resistant bacteria; Drug shortages negatively affect patient safety, costs of care.
-
New research suggests that AIDS therapy should be initiated at higher CD4 levels than current guidelines recommend. In the study, published in the Sept. 15 issue of The Journal of Infectious Diseases, researchers wanted to reevaluate the optimal time to initiate highly active antiretroviral therapy (HAART).
-
New HIV guidelines address long-term management in the context of a persons overall life and health and emphasize the importance of strategies to improve adherence to drug regimens.
-
The recent withdrawal of the popular arthritis drug rofecoxib (Vioxx) from the market has left patients scrambling for alternatives and providers looking at long-term consequences.
